Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02823405
Title Neoadjuvant X4P-001 and Pembrolizumab in Patients With Resectable Melanoma (X4P-001-MELA)
Acronym X4P-001-MELA
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors X4 Pharmaceuticals
Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.